A Phase 2 interventional study of tucatinib and capecitabine in HER2 Positive Breast Cancer, sponsored by Seagen Inc.. Completed at 176 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-08-14.
Sponsored by Seagen Inc. (part of Pfizer) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies testing tucatinib in Breast Neoplasms — 7 open to participants now, 19 under way, 3 of them phase 3. tucatinib · Breast Neoplasms.
Among the 31 studies testing tucatinib in Breast Neoplasms, this one is the 4th largest by enrollment, is the only one that started in 2016, is one of 16 in phase 2, and was the 5th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →7 of the 31 studies testing tucatinib in Breast Neoplasms are open now, in 4 countries. Recruiting first, the newest first:
Institut Curie · Sites in France
Ages 18+
Dana-Farber Cancer Institute · Sites in United States
Ages 18+
Institut Curie · Sites in France
Ages 18+
The Netherlands Cancer Institute · Sites in Netherlands
Ages 18+
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 18+
By country, each count listing its studies:
tucatinib: first FDA approval 2020 (TUKYSA), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, tucatinib is the treatment under test here. Read study by study →
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 22 · Phase 3 3
First in 2010; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 612 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 41 across the 31 interventional studies. Of the 9 that completed or were terminated, 4 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 31 have an industry lead sponsor. The 10 most frequent:
This study is registered under Seagen Inc., one of the names counted as Pfizer. Under that name alone:
Seagen Inc. is the lead sponsor of 88 studies on the registry; 1 is open to participants now.
Of its 27 completed or terminated interventional studies of FDA-regulated products, 14 (52%) have results posted.
182 studies in Breast Neoplasms by Pfizer: 6 open now, 26 under way, 7 of them phase 3. Of 145 finished, 94 (65%) have results posted.
Among the 182 studies in Breast Neoplasms by Pfizer, this one is the 12th largest by enrollment of the 121 interventional ones that give a count, is one of 6 that started in 2016, is one of 43 in phase 2, and was the 88th registered.
Pfizer’s Breast Neoplasms studies by the year they started, since 1998.
5 of the studies testing tucatinib in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05382364PfizerSafety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002) | 2026-12-31 |
| NCT06016387Sunnybrook Health Sciences CentreTucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study | 2026-12-31 |
| NCT05319873Jonsson Comprehensive Cancer CenterRibociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer | 2027-04-01 |
| NCT05458674Criterium, Inc.Tucatinib+Trastuzumab+Eribulin in HER2+ MBC | 2027-06-01 |
| NCT05748834SCRI Development Innovations, LLCStudy of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer | 2027-11 |
Add all 5 to your calendar (.ics) → With an account.
Among the 31 studies testing tucatinib in Breast Neoplasms, from their registry updates:
Among Pfizer’s 182 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This study is being done to see if tucatinib works better than placebo to help patients who have a specific type of breast cancer called HER2 positive breast carcinoma. The breast cancer in this study is either metastatic (spread into other parts of the body) or cannot be removed completely with surgery. All patients in the study will get capecitabine and trastuzumab, two drugs that are often used to treat this cancer.
There are two parts to this study. The first part of the study is already complete. Patients were randomly assigned to get either tucatinib or placebo (a pill with no medicine). Since this part was "blinded," neither patients nor their doctors knew whether a patient got tucatinib or placebo.
The second part of the study is called the Unblinded Phase. In this part of the study, participants and their doctors know which drugs are being given. Participants who used to get or are currently getting placebo may be able to start taking tucatinib instead.
Each treatment cycle lasts 21 days. Patients will swallow tucatinib pills two times every day. They will swallow capecitabine pills two times a day during the first two weeks of each cycle. Patients will get trastuzumab injections from the study site staff on the first day of every cycle.
This is a randomized, international, multi-center study in patients with progressive unresectable locally advanced or metastatic HER2+ breast cancer who have had prior treatment with trastuzumab, pertuzumab and T-DM1. There are two phases to this trial: the Double-blind Phase and the Unblinded Phase. In the Double-blind phase, participants were randomized in a 2:1 ratio to receive tucatinib or placebo in combination with capecitabine and trastuzumab. In the Unblinded Phase, patients on placebo may be offered tucatinib.
Stratification factors include presence or history of treated or untreated brain metastases or brain lesions of equivocal significance (yes/no), Eastern Cooperative Oncology Group (ECOG) Performance Status (0 vs. 1), and region of world (US vs. Canada vs. Rest of World).
Safety assessments will be performed at a minimum of once every three weeks throughout study treatment and 30 days after the last dose of study drugs. Laboratory assessments will be performed locally at sites. Left ventricular ejection fraction will be assessed by MUGA or ECHO at screening and once every 12 weeks thereafter.
For the blinded phase, contrast brain MRI was performed at baseline. Efficacy assessments (CT of chest, abdomen and pelvis at a minimum) utilized RECIST 1.1 and included patients with evaluable tumors defined as measurable target lesions and non-measurable non-target lesions. RECIST assessment was performed at baseline, every 6 weeks for the first 24 weeks, and then every 9 weeks thereafter. Repeat MRI of the brain was required on this same schedule only in those patients with brain metastases identified at baseline. All treatment decisions were made based upon investigator assessment. All patients underwent a repeat MRI of the brain within 30 days of the end of treatment unless previously performed at time of disease progression.
For the unblinded phase, RECIST assessments will be performed per standard clinical practice as determined by investigator with a maximum interval of 12 weeks.
Double-blind Phase Inclusion Criteria
CNS Inclusion - Based on screening brain magnetic resonance imaging (MRI), patients must have one of the following:
Previously treated brain metastases not needing immediate local therapy
i. Time since whole brain radiation therapy (WBRT) is ≥ 21 days prior to first dose of study treatment, time since stereotactic radiosurgery (SRS) is ≥ 7 days prior to first dose of study treatment, or time since surgical resection is ≥ 28 days.
ii. Other sites of disease assessable by RECIST 1.1 are present
Double-blind Phase Exclusion Criteria
Previously been treated with:
CNS Exclusion - Based on screening brain MRI, patients must not have any of the following:
CNS Inclusion - Based on screening brain magnetic resonance imaging (MRI), patients must have one of the following:
i. No evidence of brain metastases ii. Untreated brain metastases not needing immediate local therapy iii. Previously treated brain metastases not needing immediate local therapy
Patients treated with CNS local therapy for newly identified lesions found on contrast brain MRI performed during screening for this study may be eligible to enroll if the following criteria are met:
History of exposure to the following cumulative doses of anthracyclines:
History of allergic reactions to trastuzumab, capecitabine, or compounds chemically or biologically similar to tucatinib
o Exceptions for Grade 1 or 2 infusion related reactions to trastuzumab that were successfully managed, or known allergy to one of the in the study drugs
Any toxicity related to prior cancer therapies that has not resolved to ≤ Grade 1, with the following exceptions:
CNS Exclusion - Based on screening brain MRI, patients must not have any of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tucatinib + capecitabine + trastuzumab
Drug: tucatinib · Drug: capecitabine · Drug: trastuzumab
Placebo + capecitabine + trastuzumab
Drug: capecitabine · Drug: trastuzumab · Drug: placebo
300 mg orally twice daily
Also known as: ONT-380, ARRY-380
1000 mg/m2 orally twice daily on Days 1-14 of each 21-day cycle
Also known as: Xeloda
8 mg/kg intravenously (IV) on Day 1 of Cycle 1, followed by 6 mg/kg on Day1 of each 21-day cycle. In regions where approved, trastuzumab may be given at 600mg subcutaneously once every 3-weeks at either study initiation or crossing over from previous IV trastuzumab.
Also known as: Herceptin, Herceptin Hycleta
Oral dose twice daily
Progression-free Survival (PFS) Per RECIST 1.1 as Determined by Blinded Independent Central Review (BICR)
Defined as the time from the date of randomization to the date of documented disease progression.
Time frame: 34.6 months
PFS in Patients With Brain Metastases at Baseline Using RECIST 1.1 as Determined by BICR
Defined as the time from the date of randomization to the date of documented disease progression.
Time frame: 34.6 months
Overall Survival (OS) at Time of Primary Analysis
Defined as time from randomization to death from any cause
Time frame: 35.9 months
Confirmed Objective Response Rate (ORR) Per RECIST 1.1 as Determined by BICR
Defined as achieving a best overall response of confirmed complete response (CR) or confirmed partial response (PR).
Time frame: 34.6 months
ORR Per RECIST 1.1 as Determined by Investigator Assessment
Defined as achieving a best overall response of confirmed CR or confirmed PR.
Time frame: 34.6 months
PFS Per RECIST 1.1 as Determined by Investigator Assessment at Time of Primary Analysis
Defined as the time from the date of randomization to the date of documented disease progression
Time frame: 34.6 months
Duration of Response (DOR) Per RECIST 1.1 as Determined by BICR
Defined as the time from the first objective response to documented disease progression or death from any cause, whichever occurred first.
Time frame: 24.6 months
DOR Per RECIST 1.1 as Determined by Investigator Assessment
Defined as the time from the first objective response to documented disease progression or death from any cause, whichever occurred first.
Time frame: 33.2 months
Clinical Benefit Rate (CBR) as Determined by BICR Per RECIST 1.1
Clinical benefit was defined as achieving stable disease (SD) or non-complete response (CR)/non-progressive disease (PD) for at least 6 months or a best overall response of confirmed CR or confirmed partial response (PR).
Time frame: 34.6 months
CBR Per RECIST 1.1 as Determined by Investigator Assessment
Clinical benefit was defined as achieving stable disease (SD) or non-CR/non-PD for at least 6 months or a best overall response of confirmed CR or confirmed PR.
Time frame: 34.6 months
Incidence of Adverse Events (AEs) at Time of Primary Analysis
As determined by assessment of AEs, clinical laboratory tests, and vital signs measurements. AEs were classified by system organ class (SOC) and preferred term using the Medical Dictionary for Regulatory Activities (MedDRA) Version 22.0 or higher; AE severities were classified using Version 4.03 of the (Common Terminology Criteria for Adverse Events) CTCAE criteria.
Time frame: 36.1 months
Frequency of Dose Modifications
Time frame: 35.1 months
Incidence of Health Resources Utilization
Cumulative incidence of health resource utilization, including length of stay, hospitalizations, and ER visits using the EQ-5D-5L questionnaire.
Time frame: 36.1 months
Pharmacokinetic Measure: Ctrough of Tucatinib
Individual plasma tucatinib concentrations at each sampling time
Time frame: 3.5 months
Pharmacokinetic Measure: ONT-993
Individual plasma primary metabolite concentrations at each sampling time
Time frame: 3.5 months
Overall Survival (OS) at Time of Final Analysis
Defined as time from randomization to death from any cause
Time frame: Up to 60.1 months
PFS Per RECIST 1.1 as Determined by Investigator Assessment at Time of Final Analysis
Defined as the time from the date of randomization to the date of documented disease progression
Time frame: Up to 58.0 months
Incidence of Adverse Events (AEs) at Time of Final Analysis
As determined by assessment of AEs, clinical laboratory tests, and vital signs measurements. AEs were classified by system organ class (SOC) and preferred term using the Medical Dictionary for Regulatory Activities (MedDRA) Version 22.0 or higher; AE severities were classified using Version 4.03 of the (Common Terminology Criteria for Adverse Events) CTCAE criteria.
Time frame: Up to 60.1 months
Frequency of Dose Modifications at Time of Final Analysis
Time frame: Up to 60.1 months
| Milestone | Tuc+Cap+Tra | Pbo+Cap+Tra |
|---|---|---|
| Started | 410 | 202 |
| Completed | 0 | 0 |
| Not completed | 410 | 202 |
| Withdrew: Death | 258 | 151 |
| Withdrew: Study closure by sponsor | 119 | 45 |
| Withdrew: Withdrawal by subject | 24 | 5 |
| Withdrew: Lost to follow-up | 7 | 0 |
| Withdrew: Physician decision | 1 | 1 |
| Withdrew: Hospital closure | 1 | 0 |
Defined as the time from the date of randomization to the date of documented disease progression.
| months | Tuc+Cap+Tra | Pbo+Cap+Tra |
|---|---|---|
| Progression-free Survival (PFS) Per RECIST 1.1 as Determined by Blinded Independent Central Review (BICR) | 7.8 (4.3 to 17.8) | 5.6 (3.0 to 9.7) |
Defined as the time from the date of randomization to the date of documented disease progression.
| months | Tuc+Cap+Tra | Pbo+Cap+Tra |
|---|---|---|
| PFS in Patients With Brain Metastases at Baseline Using RECIST 1.1 as Determined by BICR | 7.6 (4.2 to 11.8) | 5.4 (3.0 to 7.5) |
Defined as time from randomization to death from any cause
| months | Tuc+Cap+Tra | Pbo+Cap+Tra |
|---|---|---|
| Overall Survival (OS) at Time of Primary Analysis | 21.9 (18.3 to 31.0) | 17.4 (13.6 to 19.9) |
Defined as achieving a best overall response of confirmed complete response (CR) or confirmed partial response (PR).
| percentage of participants | Tuc+Cap+Tra | Pbo+Cap+Tra |
|---|---|---|
| Confirmed Objective Response Rate (ORR) Per RECIST 1.1 as Determined by BICR | 40.7 (34.8 to 46.7) | 23.4 (16.6 to 31.3) |
Defined as achieving a best overall response of confirmed CR or confirmed PR.
| percentage of participants | Tuc+Cap+Tra | Pbo+Cap+Tra |
|---|---|---|
| ORR Per RECIST 1.1 as Determined by Investigator Assessment | 41.4 (35.6 to 47.4) | 23.0 (16.3 to 30.9) |
Defined as the time from the date of randomization to the date of documented disease progression
| months | Tuc+Cap+Tra | Pbo+Cap+Tra |
|---|---|---|
| PFS Per RECIST 1.1 as Determined by Investigator Assessment at Time of Primary Analysis | 7.5 (4.1 to 13.1) | 4.3 (2.7 to 8.4) |
Defined as the time from the first objective response to documented disease progression or death from any cause, whichever occurred first.
| months | Tuc+Cap+Tra | Pbo+Cap+Tra |
|---|---|---|
| Duration of Response (DOR) Per RECIST 1.1 as Determined by BICR | 8.3 (4.3 to 12.8) | 6.3 (4.2 to 9.0) |
Defined as the time from the first objective response to documented disease progression or death from any cause, whichever occurred first.
| months | Tuc+Cap+Tra | Pbo+Cap+Tra |
|---|---|---|
| DOR Per RECIST 1.1 as Determined by Investigator Assessment | 7.0 (4.3 to 12.9) | 6.9 (4.1 to 9.6) |
Clinical benefit was defined as achieving stable disease (SD) or non-complete response (CR)/non-progressive disease (PD) for at least 6 months or a best overall response of confirmed CR or confirmed partial response (PR).
| percentage of participants | Tuc+Cap+Tra | Pbo+Cap+Tra |
|---|---|---|
| Clinical Benefit Rate (CBR) as Determined by BICR Per RECIST 1.1 | 59.8 (54.8 to 64.5) | 38.1 (31.4 to 45.2) |
Clinical benefit was defined as achieving stable disease (SD) or non-CR/non-PD for at least 6 months or a best overall response of confirmed CR or confirmed PR.
| percentage of participants | Tuc+Cap+Tra | Pbo+Cap+Tra |
|---|---|---|
| CBR Per RECIST 1.1 as Determined by Investigator Assessment | 58.0 (53.1 to 62.9) | 37.6 (30.9 to 44.7) |
As determined by assessment of AEs, clinical laboratory tests, and vital signs measurements. AEs were classified by system organ class (SOC) and preferred term using the Medical Dictionary for Regulatory Activities (MedDRA) Version 22.0 or higher; AE severities were classified using Version 4.03 of the (Common Terminology Criteria for Adverse Events) CTCAE criteria.
| Participants | Tuc+Cap+Tra | Pbo+Cap+Tra |
|---|---|---|
| Any treatment-emergent AE (TEAE) | 401 | 191 |
| Any Grade 3 or higher TEAE | 223 | 96 |
| Any treatment-emergent serious AE | 104 | 53 |
| TEAE leading to death | 8 | 6 |
| Participants | Tuc+Cap+Tra | Pbo+Cap+Tra |
|---|---|---|
| TEAEs resulting in tuc/pbo dose modification | 220 | 81 |
| TEAEs resulting in tucatinib/placebo dose hold | 216 | 80 |
| TEAEs resulting in tuc/pbo dose reduction | 84 | 21 |
| TEAEs resulting capecitabine dose modification | 313 | 122 |
| TEAEs resulting in capecitabine dose hold | 276 | 113 |
| TEAEs resulting in capecitabine dose reduction | 243 | 77 |
| TEAEs resulting trastuzumab dose modification | 104 | 38 |
| TEAEs resulting in trastuzumab dose hold | 104 | 38 |
Cumulative incidence of health resource utilization, including length of stay, hospitalizations, and ER visits using the EQ-5D-5L questionnaire.
| hospitalizations | Tuc+Cap+Tra | Pbo+Cap+Tra |
|---|---|---|
| Total number of hospitalizations | 143 | 75 |
| Hospitalization for AE | 124 | 64 |
| Planned hospitalization (other than AE) | 10 | 6 |
| Ambulatory Surgery | 3 | 0 |
| Other | 6 | 5 |
Individual plasma tucatinib concentrations at each sampling time
| ng/mL | Tuc+Cap+Tra |
|---|---|
| Cycle 2, Day 1 (Pre-dose) | 246.1 ± 260.9 |
| Cycle 3, Day 1 (Pre-dose) | 227.6 ± 210.8 |
| Cycle 3, Day 1 (Post-dose) | 507.1 ± 357.1 |
| Cycle 4, Day 1 (Pre-dose) | 253.2 ± 236.1 |
| Cycle 5, Day 1 (Pre-dose) | 257.6 ± 286.9 |
| Cycle 6, Day 1 (Pre-dose) | 247.8 ± 225.1 |
Individual plasma primary metabolite concentrations at each sampling time
| ng/mL | Tuc+Cap+Tra |
|---|---|
| Cycle 2, Day 1 (Pre-dose) | 25.5 ± 24.4 |
| Cycle 3, Day 1 (Pre-dose) | 22.6 ± 20.6 |
| Cycle 3, Day 1 (Post-dose) | 47.7 ± 47.2 |
| Cycle 4, Day 1 (Pre-dose) | 25.2 ± 24.3 |
| Cycle 5, Day 1 (Pre-dose) | 24.5 ± 30.6 |
| Cycle 6, Day 1 (Pre-dose) | 20.9 ± 18.0 |
Defined as time from randomization to death from any cause
| months | Tuc+Cap+Tra | Pbo+Cap+Tra |
|---|---|---|
| Overall Survival (OS) at Time of Final Analysis | 24.7 (21.6 to 28.9) | 19.2 (16.4 to 21.4) |
Defined as the time from the date of randomization to the date of documented disease progression
| months | Tuc+Cap+Tra | Pbo+Cap+Tra |
|---|---|---|
| PFS Per RECIST 1.1 as Determined by Investigator Assessment at Time of Final Analysis | 7.6 (4.1 to 13.8) | 4.9 (2.7 to 9.0) |
As determined by assessment of AEs, clinical laboratory tests, and vital signs measurements. AEs were classified by system organ class (SOC) and preferred term using the Medical Dictionary for Regulatory Activities (MedDRA) Version 22.0 or higher; AE severities were classified using Version 4.03 of the (Common Terminology Criteria for Adverse Events) CTCAE criteria.
| Participants | Tuc+Cap+Tra | Pbo+Cap+Tra |
|---|---|---|
| Any treatment-emergent AE (TEAE) | 401 | 191 |
| Any Grade 3 or higher TEAE | 248 | 101 |
| Any treatment-emergent serious AE | 123 | 58 |
| TEAE leading to death | 8 | 6 |
| Participants | Tuc+Cap+Tra | Pbo+Cap+Tra |
|---|---|---|
| TEAEs resulting in tuc/pbo dose modification | 237 | 85 |
| TEAEs resulting in tucatinib/placebo dose hold | 232 | 84 |
| TEAEs resulting in tuc/pbo dose reduction | 92 | 21 |
| TEAEs resulting capecitabine dose modification | 322 | 125 |
| TEAEs resulting in capecitabine dose hold | 288 | 117 |
| TEAEs resulting in capecitabine dose reduction | 251 | 79 |
| TEAEs resulting trastuzumab dose modification | 117 | 41 |
| TEAEs resulting in trastuzumab dose hold | 117 | 41 |
Collected over Non-serious Adverse Events, Serious Adverse Events, and All-Cause Mortality were followed for up to 60.1 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tuc+Cap+Tra | 262/410 (63.9%) | 124/404 (30.7%) | 399/404 (98.8%) |
| Pbo+Cap+Tra | 152/202 (75.2%) | 62/197 (31.5%) | 188/197 (95.4%) |
| Event | Tuc+Cap+Tra | Pbo+Cap+Tra |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 17/404 | 7/197 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 6/404 | 7/197 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 3/404 | 6/197 |
| VomitingGastrointestinal disorders | 11/404 | 5/197 |
| SeizureNervous system disorders | 11/404 | 2/197 |
| NauseaGastrointestinal disorders | 9/404 | 4/197 |
| HypokalaemiaMetabolism and nutrition disorders | 1/404 | 4/197 |
| PneumoniaInfections and infestations | 8/404 | 3/197 |
| Ejection fraction decreasedInvestigations | 6/404 | 3/197 |
| HeadacheNervous system disorders | 2/404 | 3/197 |
| Event | Tuc+Cap+Tra | Pbo+Cap+Tra |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 330/404 | 106/197 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 265/404 | 105/197 |
| NauseaGastrointestinal disorders | 243/404 | 87/197 |
| FatigueGeneral disorders | 193/404 | 87/197 |
| VomitingGastrointestinal disorders | 155/404 | 49/197 |
| Decreased appetiteMetabolism and nutrition disorders | 108/404 | 41/197 |
| StomatitisGastrointestinal disorders | 105/404 | 28/197 |
| HeadacheNervous system disorders | 98/404 | 38/197 |
| Aspartate aminotransferase increasedInvestigations | 92/404 | 23/197 |
| AnaemiaBlood and lymphatic system disorders | 89/404 | 24/197 |
Intent-to-treat Overall Survival (ITT-OS) Population: Includes all randomized participants evaluated by their randomized treatment assignment.
| Age, Categorical(Participants) | Tuc+Cap+Tra | Pbo+Cap+Tra | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 328 | 168 | 496 |
| >=65 years | 82 | 34 | 116 |
| Age, Continuous(years) | Tuc+Cap+Tra | Pbo+Cap+Tra | Total |
|---|---|---|---|
| Median | 55 (22 to 80) | 54 (25 to 82) | 54 (22 to 82) |
| Sex: Female, Male(Participants) | Tuc+Cap+Tra | Pbo+Cap+Tra | Total |
|---|---|---|---|
| Female | 407 | 200 | 607 |
| Male | 3 | 2 | 5 |
| Ethnicity (NIH/OMB)(Participants) | Tuc+Cap+Tra | Pbo+Cap+Tra | Total |
|---|---|---|---|
| Hispanic or Latino | 37 | 14 | 51 |
| Not Hispanic or Latino | 362 | 184 | 546 |
| Unknown or Not Reported | 11 | 4 | 15 |
| Race (NIH/OMB)(Participants) | Tuc+Cap+Tra | Pbo+Cap+Tra | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 18 | 5 | 23 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 41 | 14 | 55 |
| White | 287 | 157 | 444 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 64 | 26 | 90 |
| Region of Enrollment(Participants) | Tuc+Cap+Tra | Pbo+Cap+Tra | Total |
|---|---|---|---|
| United States | 220 | 111 | 331 |
| France | 29 | 17 | 46 |
| United Kingdom | 33 | 12 | 45 |
| Australia | 27 | 12 | 39 |
| Canada | 26 | 12 | 38 |
| Spain | 19 | 7 | 26 |
| Denmark | 13 | 7 | 20 |
| Germany | 9 | 8 | 17 |
| Israel | 13 | 3 | 16 |
| Belgium | 4 | 6 | 10 |
| Italy | 6 | 3 | 9 |
| Austria | 6 | 1 | 7 |
| Portugal | 3 | 1 | 4 |
| Czech Republic | 2 | 1 | 3 |
| Switzerland | 0 | 1 | 1 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants) | Tuc+Cap+Tra | Pbo+Cap+Tra | Total |
|---|---|---|---|
| 0: Normal activity | 204 | 94 | 298 |
| 1: Symptoms, but ambulatory | 206 | 108 | 314 |
Showing the first 100 of 176 sites across 15 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2016 to primary completion in Sep 2019, 43 months.
Results were first posted in Sep 2020, 1 year after primary completion.
Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 43 months is above that.
Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tucatinib